Search

Your search keyword '"Yorke, Janelle"' showing total 5 results
Start Over Author "Yorke, Janelle" Journal bmc cancer
5 results on '"Yorke, Janelle"'

2. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy

Author

Molassiotis, Alex, Cheng, Hui Lin, Lopez, Violeta, Au, Joseph SK, Chan, Alexandre, Bandla, Aishwarya, Leung, KT, Li, YC, Wong, KH, Suen, Lorna KP, Chan, Choi Wan, Yorke, Janelle, Farrell, Carole, and Sundar, Raghav

Subjects
Neurodegenerative, Cancer, Peripheral Neuropathy, Neurosciences, Clinical Research, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Dose-Response Relationship, Drug, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neoplasm Staging, Neoplasms, Patient Reported Outcome Measures, Peripheral Nervous System Diseases, Prevalence, Prospective Studies, Quality of Life, Severity of Illness Index, Peripheral neuropathy, Neurotoxicity, Chemotherapy, Assessment, Taxanes, Platins, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThere are inconsistencies in the literature regarding the prevalence and assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored CIPN natural history and its characteristics in patients receiving taxane- and platinum-based chemotherapy.Patients and methodsMulti-country multisite prospective longitudinal observational study. Patients were assessed before commencing and three weekly during chemotherapy for up to six cycles, and at 6,9, and 12 months using clinician-based scales (NCI-CTCAE; WHO-CIPN criterion), objective assessments (cotton wool test;10 g monofilament); patient-reported outcome measures (FACT/GOG-Ntx; EORTC-CIPN20), and Nerve Conduction Studies.ResultsIn total, 343 patients were recruited in the cohort, providing 2399 observations. There was wide variation in CIPN prevalence rates using different assessments (14.2-53.4%). Prevalence of sensory neuropathy (and associated symptom profile) was also different in each type of chemotherapy, with paclitaxel (up to 63%) and oxaliplatin (up to 71.4%) showing the highest CIPN rates in most assessments and a more complex symptom profile. Peak prevalence was around the 6-month assessment (up to 71.4%). Motor neurotoxicity was common, particularly in the docetaxel subgroup (up to 22.1%; detected by NCI-CTCAE). There were relatively moderately-to-low correlations between scales (rs = 0.15,p

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results